<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Niraparib and abiraterone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Niraparib and abiraterone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Niraparib and abiraterone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="142705" href="/d/html/142705.html" rel="external">see "Niraparib and abiraterone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58642746"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Akeega</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58682437"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Akeega</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58552258"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiandrogen;</li>
<li>
                        Antineoplastic Agent, Antiandrogen;</li>
<li>
                        Antineoplastic Agent, PARP Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F58599936"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not initiate niraparib/abiraterone acetate until after adequately recovered from hematologic toxicity due to previous therapy. Control hypertension and correct hypokalemia prior to and during niraparib/abiraterone acetate treatment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9addb499-e701-4f63-902d-60aef5057685">Prostate cancer, metastatic, castration resistant, <i>BRCA</i>-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant, <i>BRCA</i>-mutated: Oral:</b> Niraparib 200 mg/abiraterone acetate 1,000 mg once daily (in combination with prednisone); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36952634','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36952634','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Patients receiving niraparib/abiraterone acetate should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently (or should have had a bilateral orchiectomy).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> If a dose is missed, administer the dose as soon as possible on the same day and resume the next dose at the regularly scheduled time on the next day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58599939"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Monitor for increased adverse reactions and modify dosage as recommended for adverse reactions.</p></div>
<div class="block doha drugH1Div" id="F58599940"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Initial dose with preexisting liver cirrhosis</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Turcotte-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment (Child-Turcotte-Pugh class B, C): Avoid niraparib/abiraterone acetate use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for hepatotoxicity during treatment:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">ALT and/or AST &gt;5 times ULN or total bilirubin &gt;3 times ULN: Withhold niraparib/abiraterone acetate and closely monitor liver function. When AST and ALT resolve to ≤2.5 times ULN and total bilirubin is ≤1.5 times ULN, may resume at a reduced dose of niraparib 100 mg/abiraterone acetate 500 mg once daily with serum transaminase monitoring every 2 weeks for 3 months, then monthly thereafter (and as clinically indicated).</p>
<p style="text-indent:-2em;margin-left:4em;">Concurrent elevation of ALT &gt;3 times ULN and total bilirubin &gt;2 times ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation: Permanently discontinue niraparib/abiraterone acetate.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST ≥20 times ULN at any time: Permanently discontinue niraparib/abiraterone acetate.</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent hepatotoxicity at a dose of niraparib 100 mg/abiraterone acetate 500 mg: Permanently discontinue niraparib/abiraterone acetate.</p></div>
<div class="block dot drugH1Div" id="F58599953"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not reinitiate niraparib/abiraterone acetate until toxicity has resolved to ≤ grade 1. If the toxicity is attributed to one component of niraparib/abiraterone acetate, the other component may be continued (as a single agent) at the current dose until the adverse reaction resolves and niraparib/abiraterone acetate can be resumed. See "Dosage Modification" table.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Niraparib/Abiraterone Acetate Recommended Dosage Modifications for Adverse Reactions<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Niraparib dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> MDS = myelodysplastic syndrome; AML = acute myeloid leukemia; PRES = posterior reversible encephalopathy syndrome.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Anemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hemoglobin &lt;8 g/dL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold niraparib/abiraterone acetate and monitor blood counts weekly. When hemoglobin is ≥9 g/dL, resume at a reduced dose of niraparib 100 mg/abiraterone acetate 1,000 mg once daily and monitor blood counts weekly for 28 days or as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate if hemoglobin has not returned to acceptable levels within 28 days of interrupting the dose, or if dose has already been reduced to niraparib 100 mg/abiraterone acetate 1,000 mg once daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutrophils &lt;1,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold niraparib/abiraterone acetate and monitor blood counts weekly. When neutrophils are ≥1,500/mm<sup>3</sup>, resume at a reduced dose of niraparib 100 mg/abiraterone acetate 1,000 mg once daily and monitor blood counts weekly for 28 days or as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate if neutrophils have not returned to acceptable levels within 28 days of interrupting the dose, or if dose has already been reduced to niraparib 100 mg/abiraterone acetate 1,000 mg once daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;100,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>First occurrence</i>: Withhold niraparib/abiraterone acetate for a maximum of 28 days and monitor blood counts weekly. When platelets are ≥100,000/mm<sup>3</sup>, resume at the same dose or at a reduced dose of niraparib 100 mg/abiraterone acetate 1,000 mg once daily. If platelet count was &lt;75,000/mm<sup>3</sup>, resume at reduced dose of niraparib 100 mg/abiraterone acetate 1,000 mg once daily.</p>
<p style="text-indent:0em;text-align:left;">
<i>Second occurrence:</i> Withhold niraparib/abiraterone acetate for a maximum of 28 days and monitor blood counts weekly. When platelets are ≥100,000/mm<sup>3</sup>, resume at reduced dose of niraparib 100 mg/abiraterone acetate 1,000 mg once daily.</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate if platelet count has not returned to acceptable levels within 28 days of interrupting dose, or if dose has already been reduced to niraparib 100 mg/abiraterone acetate 1,000 mg once daily.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transfusion dependence</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold niraparib/abiraterone acetate; resume at a reduced dose of niraparib 100 mg/abiraterone acetate 1,000 mg once daily.</p>
<p style="text-indent:0em;text-align:left;">Consider platelet transfusion for platelets ≤10,000/mm<sup>3</sup>. If other risk factors (eg, concurrent anticoagulation or antiplatelet therapy), consider interrupting the anticoagulant/antiplatelet therapy and/or transfusing to a higher platelet count.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Persistent (&gt;28 days following treatment interruption)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate.</p>
<p style="text-indent:0em;text-align:left;">Obtain consult with hematology for further assessment, including bone marrow and cytogenetic analysis.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Secondary MDS or AML</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Suspected</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Refer to a hematologist for further evaluation if MDS/AML is suspected.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Confirmed</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b></b>Adrenocortical insufficiency</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increased doses of corticosteroids may be indicated before, during, and after stressful situations.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cardiovascular adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertensive crisis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">PRES</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Suspected</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate. Manage appropriately if suspected; the safety of reinitiating niraparib/abiraterone in patients previously experiencing PRES is not known.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Other treatment-related adverse reaction that persist despite medical management</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold niraparib/abiraterone acetate for a maximum of 28 days or until resolution. If resolves in ≤28 days, resume niraparib/abiraterone at a reduced dose.</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue niraparib/abiraterone acetate if adverse reaction(s) has not resolved after 28 days or for recurrent grade 3 or 4 adverse reaction after dose reduction.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F58599938"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58569610"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults receiving concomitant prednisone.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (17%), hypertension (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium (20%), increased serum potassium (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (12%), constipation (34%), decreased appetite (15%), nausea (33%), vomiting (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (67%; grades 3/4: 26% to 28%), decreased white blood cell count (48%; grades 3/4: 6%), hemorrhage (4% to 12%; grade 3/4: 2%), lymphocytopenia (55%; grades 3/4: 22%), neutropenia (32%; grades 3/4: 7%), thrombocytopenia (37%; grades 3/4: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (5% to 18%), increased serum alkaline phosphatase (34%), increased serum aspartate aminotransferase (5% to 20%), increased serum bilirubin (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (14%), fatigue (43%), headache (12%), insomnia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (44%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (12%), dyspnea (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (10%), deep vein thrombosis (3%), pulmonary embolism (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (4%), falling (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia</p></div>
<div class="block coi drugH1Div" id="F58552260"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58599809"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Niraparib/abiraterone acetate may cause adrenal insufficiency; adrenocortical insufficiency has been reported with abiraterone acetate (in combination with prednisone), following interruption of daily corticosteroids and/or with concurrent infection or stress. The risk for adrenocortical insufficiency may be increased if prednisone is withdrawn, with prednisone dose reductions, or with unusual stress. Signs/symptoms of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess. If clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical insufficiency. Increased doses of corticosteroids may be indicated before, during, and after stressful situations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Niraparib/abiraterone acetate may cause myelosuppression (anemia, thrombocytopenia, or neutropenia), including grade 3 and 4 events. Some patients required red blood cell transfusions, while some patients required multiple transfusions. A small percentage of patients required discontinuation due to anemia. Prolonged hematologic toxicity may require hematology evaluation for bone marrow analysis and cytogenetics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Niraparib/abiraterone acetate may cause hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels due to CYP17 inhibition. QT prolongation and torsades de pointes have been observed in patients who develop abiraterone-associated hypokalemia. Hypertension and hypertensive crisis have also been reported with niraparib. In a cohort of the clinical study that used prednisone 10 mg/day in combination with niraparib/abiraterone acetate, grades 3 to 4 hypokalemia were reported in a small percentage of patients in the niraparib/abiraterone acetate arm; grades 3 to 4 hypertension were also observed in the niraparib/abiraterone acetate arm. Patients with New York Heart Association class II to IV heart failure were excluded from the clinical trial and safety has not been established in these patients. Patients with underlying medical conditions (eg, heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia) could be compromised by increases in BP, hypokalemia, or fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Niraparib/abiraterone acetate may cause hepatotoxicity. Hepatotoxicity has been reported with abiraterone acetate; may be severe, including fulminant hepatitis, acute liver failure, and deaths. Grade 3 or 4 ALT or AST elevations have been reported in a small percentage of patients. Patients with moderate or severe hepatic impairment were excluded from the clinical trial and the safety of niraparib/abiraterone acetate in these patients has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoglycemia: Niraparib/abiraterone acetate may cause hypoglycemia in patients being treated with other medications for diabetes; severe hypoglycemia has been reported when abiraterone acetate is administered to patients also receiving medications containing thiazolidinediones (including pioglitazone) or repaglinide. Assess if antidiabetic therapy needs to be adjusted to minimize the risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Posterior reversible encephalopathy syndrome: Niraparib/abiraterone acetate may cause posterior reversible encephalopathy syndrome (PRES). PRES has been observed with niraparib (as a single agent) at doses higher than the recommended dose of niraparib/abiraterone acetate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Niraparib/abiraterone acetate may cause myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), including cases with fatal outcome. MDS/AML has been observed with niraparib; all patients who developed treatment-related secondary MDS/AML had received prior chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy. Refer to a hematologist for further evaluation if MDS/AML is suspected and/or for prolonged hematological toxicities. <i>
<b></b></i></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Radium Ra 223 dichloride: Due to an increase in the incidence of fractures and a risk for mortality, niraparib/abiraterone (with prednisone) is not recommended for use in combination with Ra-223 dichloride outside of a clinical trial. Subsequent treatment with Ra-223 should not be initiated for at least 5 days after the last niraparib/abiraterone acetate (with prednisone) dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for therapy based on the presence of deleterious or suspected deleterious <i>BRCA</i> mutation. Information on approved tests may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=142418" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F58642747"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Akeega: Abiraterone acetate 500 mg and niraparib tosylate 50 mg, Abiraterone acetate 500 mg and niraparib tosylate 100 mg</p></div>
<div class="block geq drugH1Div" id="F58642745"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58659616"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Akeega Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-500 mg (per each): $375.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100-500 mg (per each): $375.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58682438"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Akeega: Abiraterone acetate 500 mg and niraparib tosylate 50 mg, Abiraterone acetate 500 mg and niraparib tosylate 100 mg</p></div>
<div class="block adm drugH1Div" id="F58599955"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer on an empty stomach, at least 1 hour before and 2 hours after food (per the manufacturer); no food should be consumed for at least 2 hours before or for at least 1 hour after the dose. Swallow tablets whole with water. Do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Caregivers who are or could become pregnant should wear gloves when handling niraparib/abiraterone acetate.</p></div>
<div class="block hazard drugH1Div" id="F58599812"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone acetate: Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:-2em;margin-left:2em;">Niraparib: This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Niraparib may cause carcinogenicity, teratogenicity, reproductive toxicity, and genotoxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F58552262"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Prostate cancer, metastatic, castration resistant, <i>BRCA</i>-mutated:</b> Treatment of deleterious or suspected deleterious <i>BRCA</i>-mutated (<i>BRCA</i>m) metastatic castration-resistant prostate cancer (mCRPC) (in combination with prednisone) in adults. Select patients for therapy based on an approved test.</p></div>
<div class="block mst drugH1Div" id="F58599776"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Niraparib/abiraterone acetate may be confused with abiraterone, niraparib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58333506"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F58333503"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amoxapine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amoxapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apalutamide: May enhance the adverse/toxic effect of Niraparib. Apalutamide may decrease the serum concentration of Niraparib. Management: Consider alternatives to this combination when possible. If combined, monitor for decreased niraparib concentrations and efficacy, as well as for increased niraparib toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Atomoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose when treating indications other than major depressive disorder.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ClomiPRAMINE. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Abiraterone Acetate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Abiraterone Acetate. Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Daprodustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Dextromethorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Topical): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Abiraterone Acetate may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Imipramine. Concentrations of desipramine may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Imipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofepramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lofepramine. The active metabolite of lofepramine is desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoclopramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nortriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Protriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radium Ra 223 Dichloride: May enhance the adverse/toxic effect of Abiraterone Acetate. Specifically, the risk for fractures and death may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Abiraterone Acetate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Abiraterone Acetate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the therapeutic effect of Abiraterone Acetate. Management: Consider alternatives to the combined use of spironolactone and abiraterone. If combined, monitor the clinical response to abiraterone closely, looking specifically for signs of clinical failure and/or disease progression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Abiraterone Acetate may enhance the hypoglycemic effect of Thiazolidinediones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Trimipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F58599811"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;">Administration of abiraterone acetate with food results in up to a 10-fold increase in AUC and up to a 17-fold increase in C<sub>max</sub>, depending on the fat content of the meal (compared with administration in a fasted state). Management: Do not administer niraparib/abiraterone acetate with food; administer on an empty stomach, at least 1 hour before and 2 hours after food.</p></div>
<div class="block rep_considerations drugH1Div" id="F58599788"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with partners who could become pregnant should use effective contraception during therapy and for 4 months after the last dose of niraparib/abiraterone acetate.</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends caregivers who are or could become pregnant wear gloves when handling niraparib/abiraterone acetate tablets.</p></div>
<div class="block pri drugH1Div" id="F58599789"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to niraparib/abiraterone acetate may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F58599790"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if niraparib or abiraterone acetate are present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F58599957"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC (monitor weekly during the first month of niraparib/abiraterone acetate treatment, every 2 weeks for the next 2 months, monthly for the remainder of the first year, and then every other month and as clinically indicated; monitor weekly if hematologic toxicity occurs). Prolonged hematologic toxicity may require hematology evaluation for bone marrow analysis and cytogenetics. Monitor serum transaminases (ALT and AST) and bilirubin levels prior to treatment initiation, every 2 weeks for the first 3 months, then monthly thereafter (monitor more frequently if elevations occur); if clinical symptoms or signs suggestive of hepatotoxicity develop, promptly assess serum total bilirubin, AST, and ALT, and monitor every 2 weeks for 3 months, then monthly thereafter (and as clinically indicated). Monitor serum potassium (baseline, at least weekly for the first 2 months, then monthly). Monitor blood glucose (in patients with diabetes) during treatment and after discontinuation. Assess antidiabetic therapy (in patients with diabetes) for possible dosage adjustments to minimize the risk for hypoglycemia. Monitor BP (at least weekly for the first 2 months, then monthly). Monitor for signs/symptoms of fluid retention (at least weekly for the first 2 months, then monthly). Closely monitor for hypertension, hypokalemia, and fluid retention in patients with underlying medical conditions (eg, heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia). Monitor for signs/symptoms of adrenocortical insufficiency, particularly if prednisone is withdrawn, with prednisone dose reductions, or with unusual stress. Monitor for signs/symptoms of hepatotoxicity, hypoglycemia, posterior reversible encephalopathy syndrome, and /or secondary malignancy. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F58599814"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Niraparib is a poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP-1 and PARP-2. PARP-1 and PARP-2 are involved in DNA repair. Inhibiting PARP enzymatic activity forms PARP-DNA complexes that result in DNA damage, apoptosis, and cell death. Niraparib induces cytotoxicity in tumor cell lines with and without <i>BRCA</i>1/2 deficiencies.</p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone acetate is converted to abiraterone, which is an androgen biosynthesis inhibitor. Abiraterone inhibits CYP17 (17 alpha-hydroxylase/C17,20-lyase), an enzyme required for androgen biosynthesis, which is expressed in testicular, adrenal, and prostatic tumor tissues. It inhibits the formation of the testosterone precursors dehydroepiandrosterone (DHEA) and androstenedione.</p></div>
<div class="block phk drugH1Div" id="F58599830"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Niraparib: 1,117 L; Abiraterone: 25,774 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Niraparib: 83% (to plasma proteins); Abiraterone: &gt;99% (to plasma proteins and alpha-1 acid glycoprotein).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Niraparib: Metabolized by carboxylesterases; Abiraterone acetate: Rapidly converted in vivo to abiraterone and further metabolized via CYP3A4 and SULT2A1.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Niraparib: ~73%; Abiraterone acetate: Systemic exposure is increased by food.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Niraparib: ~62 hours; Abiraterone: ~20 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Niraparib: 3 hours; Abiraterone: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Niraparib: Urine (~48%; 11% as unchanged drug); feces (~39%; 19% as unchanged drug); Abiraterone: Feces (~88%; 55% as abiraterone acetate and 22% as abiraterone); urine (~5%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Niraparib: 16.7 L/hour; Abiraterone: 1,637 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F58599838"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Moderate hepatic impairment (total bilirubin &gt;1.5 to 3 times ULN and any AST) increased niraparib AUC by 56%, compared to normal hepatic function. Mild hepatic impairment (Child-Turcotte-Pugh class A) increased the abiraterone AUC by 1.1-fold and moderate hepatic impairment (Child-Turcotte-Pugh class B) increased the abiraterone AUC by 3.6-fold, compared to normal hepatic function. Severe hepatic impairment (Child-Turcotte-Pugh class C) increased abiraterone AUC by 7-fold and the fraction of free drug increased by 2-fold, compared to normal hepatic function.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>Akeega (niraparib and abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36952634">
<a name="36952634"></a>Chi KN, Rathkopf D, Smith MR, et al; MAGNITUDE Principal Investigators. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. <i>J Clin Oncol</i>. 2023;41(18):3339-3351. doi:10.1200/JCO.22.01649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niraparib-and-abiraterone-drug-information/abstract-text/36952634/pubmed" id="36952634" target="_blank">36952634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niraparib-and-abiraterone-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed August 14, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 142418 Version 20.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
